Conjugated linoleic acids, atherosclerosis, and hepatic very-low-density lipoprotein metabolism.
Conjugated linoleic acids (CLAs) are isomeric forms of the 18:2 fatty acid that contain conjugated sites of unsaturation. Although CLAs are minor components of the diet, they have many reported biological activities. For nearly a decade, the potential for CLA to modify the atherosclerotic process has been examined in animal models, and studies of supplementation of the human diet with CLA were started with the anticipation that such an intervention could also reduce the risk of cardiovascular disease. Central to the hypothesis is the expectation that dietary modification could alter plasma lipid and lipoprotein metabolism toward a more cardioprotective profile. This review examines the evidence in support of the hypothesis and the mechanistic studies that lend support for a role of CLA in hepatic lipid and lipoprotein metabolism. Although there are still limited studies in strong support of a role for CLA in the reduction of early atherosclerotic lesions, there has been considerable progress in defining the mechanisms of CLA action. CLA could primarily modulate the metabolism of fatty acids in the liver. The tools are now available to examine isomer-specific effects of CLA on hepatic lipid and lipoprotein metabolism and the potential of CLA to modify hepatic gene expression patterns. Additional animal and cell culture studies will increase our understanding of these unusual fatty acids and their potential for health benefits in humans.
McLeod
Roger S
RS
Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Canada. mcleod2@dal.ca
LeBlanc
Andrea M
AM
Langille
Morgan A
MA
Mitchell
Patricia L
PL
Currie
Deborah L
DL
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control; D019587:Dietary Supplements; D006801:Humans; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors
D044243:Linoleic Acids, Conjugated; D008079:Lipoproteins, VLDL; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors